Predict your next investment

HEALTHCARE | Drug Development
nextcure.com

See what CB Insights has to offer

Founded Year

2015

Stage

IPO | IPO

Total Raised

$185M

Date of IPO

5/9/2019

Market Cap

0.22B

Stock Price

6.93

About NextCure

NextCure (NASDAQ: NXTC) is a biopharmaceutical company focused on discovering and developing immuno-oncology-based drugs. The Company is applying its platforms and know-how to identify biologically relevant targets and develop improved immunotherapy products.

NextCure Headquarter Location

9000 Virginia Manor Suite 200

Beltsville, Maryland, 20705,

United States

240-399-4900

Latest NextCure News

NextCure To Present At The 19th Annual Morgan Stanley Global Healthcare Conference

Sep 2, 2021

NextCure To Present At The 19th Annual Morgan Stanley Global Healthcare Conference BELTSVILLE, Md., Sept. Sep 2, 2021 7:00 AM EDT BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 19 th Annual Morgan Stanley Global Healthcare Conference on September 9 th at 12:30 pm Eastern time. A live audio webcast will be available on the Investors section of the company's website at www.nextcure.com . A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com Cautionary Statement Regarding Forward-Looking StatementsStatements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change. Investor InquiriesTimothy Mayer, Ph.D.NextCure, Inc.Chief Operating Officer(240) 762-6486 IR@nextcure.com By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NextCure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NextCure is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,766 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

NextCure Patents

NextCure has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/23/2019

Clusters of differentiation, Immunology, Immune system, Transcription factors, Intracellular receptors

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/23/2019

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Intracellular receptors

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

NextCure Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NextCure Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.